CARE1 Pragmatic Clinical Trial
A legfontosabb adatok
- Ki végzi
- Gustave Roussy, Cancer Campus, Grand Paris
- Hol
- Amsterdam (Hollandia)A helyszín megnézéseMég 3 másik országban, 45 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 1250 fő, tervezett
- Kezdés
- 2024. ápr. 12.
- Várható befejezés
- 2032. máj. 5.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Nivolumab
- Ipilimumab
- Pembrolizumab
- Cabozantinib
- Axitinib
- Lenvatinib
- A regiszteradat frissítve
- 2025. január 16.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akiknek áttétes, világossejtes vesedaganatuk van, ennek kezelését még nem kezdték el, és közepes vagy rossz kockázatúak.
- Életkor
- 18 éves vagy idősebb
- Nem
- Mindkét nem részt vehet.
- A betegség stádiuma
- Áttétes (IV. stádiumú) vesesejtes vesedaganat világossejtes összetevővel, az IMDC besorolás szerint közepes vagy rossz kockázattal.
- Korábbi kezelés
- Nem lehetett korábban szisztémás daganatellenes kezelése az áttétes vesedaganatra. Egy korábbi, teljes műtét utáni adjuváns kezelés megengedett, ha a daganat legalább 6 hónappal az utolsó adag után tért vissza.
A részvétel fő kizáró okai
- Nem kontrollált agyi áttét, vagy tüneteket okozó agyi áttét
- Súlyos szív- vagy érbetegség, például III. vagy IV. osztályú szívelégtelenség, vagy szélütés az elmúlt 3 hónapban
- Autoimmun betegség, amely az elmúlt 2 évben tüneteket okozott vagy kezelést igényelt
- Kezelést igénylő aktív fertőzés, vagy másik aktív daganat
- Terhes vagy szoptató nők
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Histologically confirmed metastatic (AJCC Stage IV) renal cell carcinoma with a clear-cell component
- Intermediate- or poor-risk mRCC as defined by IMDC classification
- Adult male or female patients (≥ 18 years of age at inclusion)
- Karnofsky Performance Status (KPS) ≥70%
- Adequate organ and marrow function, according to investigator assessment and; Absolute neutrophil count (ANC) ≥ 1000/μL (≥ 1.5 GI/L); Platelets ≥ 100,000/μL (≥ 100 GI/L); Hemoglobin ≥ 8 g/dL (≥ 80 g/L); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN; Calculated creatinine clearance ≥ 30 mL/min (≥ 0.67 mL/sec) using the CKD- EPI equation
- Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed
- Patient should be able and willing to comply with study visits and procedures as per protocol
- Patients must be affiliated to a social security system or beneficiary of the same
- Female patients must either be of non-reproductive potential or must have a negative serum pregnancy test within 14 days prior to the administration of study drug. Childbearing potential women must have agreed to use one barrier method of contraception, such as condom, plus an additional highly effective method of contraception during treatment on this trial and for up to 5 months after the last dose of study treatment
- Fertile men with a female partner of childbearing potential must agree to use one barrier method of contraception, such as condom, during treatment on this trial and for up to 4 months after the last dose of treatment. Their women of childbearing potential partner must agree to use a highly effective method of contraception during the same period
- Female subjects of childbearing potential must not be pregnant at screening
Ki nem vehet részt
- Prior systemic anticancer therapy for mRCC including investigational agents. Note: One prior systemic adjuvant therapy is allowed for completely resected RCC and if recurrence occurred at least 6 months after the last dose of adjuvant therapy
- Uncontrolled brain metastases (adequately treated with radiotherapy and/or radiosurgery prior to randomization are eligible). Subjects who are neurologically symptomatic as a result of their CNS metastasis or are receiving systemic corticosteroid treatment (prednisone equivalent > 10 mg/day) at the planned time of randomization are not eligible
- Concomitant oral anti-vitamin K anticoagulation. An exception is the use of LMWH or direct oral anticoagulants (DOAC), if considered safe by investigator assessment
- The subject has uncontrolled, significant intercurrent or recent illness such as the following conditions:; Cardiovascular disorders:; Congestive heart failure (CHF) class III or IV as defined by the New York Heart Association, unstable angina pectoris, myocardial infarction, serious cardiac arrhythmias (e.g., ventricular flutter, ventricular fibrillation, Torsades de pointes); Uncontrolled hypertension despite optimal antihypertensive treatment; Stroke, or other symptomatic ischemic event or severe thromboembolic event (e.g., symptomatic pulmonary embolism [PE], incidental PE is acceptable if deemed safe by the investigator) within 3 months before randomization; Active GI bleeding or symptomatic Gastrointestinal (GI) tract obstruction; Clinically significant bleeding including uncontrolled hematuria, hematemesis, or hemoptysis; Autoimmune disease that has been symptomatic or required immunosuppressive systemic treatment within the past two years from the date of randomization; Note: Patients with a history of Crohn's disease or ulcerative colitis are always excluded; Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization; Note: Inhaled, intranasal, intra-articular, or topical steroids are permitted. Adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted. Transient short-term use of systemic corticosteroids for allergic conditions (e.g., contrast allergy) is also allowed; Active infection requiring systemic treatment; Major surgery (e.g., nephrectomy, GI surgery, removal of brain metastasis) within 4 weeks prior to randomization or serious non-healing wound/ulcer/bone fracture
- Any other active malignancy at time of randomization or diagnosis of another malignancy within 3 years prior to randomization that requires active treatment, except for locally curable cancers that have been apparently cured
- Use of live vaccines within 28 days before randomization
- Hypersensitivity to any of the active substances or to any of the excipients administered during the study
- Pregnant or breastfeeding females
- Persons deprived of their freedom or under guardianship, or for whom it would be impossible to undergo the medical follow-up required by the trial, for geographic, social or psychological reasons
Helyszínek itt: Hollandia
Még 3 másik országban, 45 helyszínen
- Antoni van LeeuwenhoekAmsterdam, HollandiaContact: Sofie Wilgenhof, MDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
Systemic therapy for renal cell carcinoma (RCC) relies on 2 classes of agents: anti-angiogenic targeted therapy (Vascular endothelial growth factor Tyrosine Kinase Inhibitor- VEGFR TKI) and immune checkpoint inhibitor (ICI), targeting either PD1/PDL1 axis or CTLA4. Combination therapy is SOC for clear cell RCC in all guidelines with either ICI-ICI or ICI-VEGFR TKI. However, no head-to-head comparison have been performed between the 2 approaches and patients are treated based on physician decision without clinical /biomarker factors to guide treatment selection. PDL1 staining is, to date, the biomarker that has demonstrated its ability to enrich for overall survival benefit favoring ICI-ICI strategy in PDL1(+) and ICI-VEGFR TKI in PDL1(-) patients.
A teljes eredeti leírásKevesebb
Study design has been developed to demonstrate that ICI-ICI is superior to ICI-VEGFR TKI in prolonging Overall Survival (OS) for PDL1(+) patients and to demonstrate that ICI-VEGFR TKI is superior to ICI-ICI in prolonging Progression Free Survival (PFS) and OS for PDL1(-) patients.
A vizsgálat 2 csoportja
- Arm A: ICI - ICI CombinationEgyéb csoport
Nivolumab (3 mg/kg infusion, every 3 weeks) x 4 doses + ipilimumab (1 mg/kg infusion, every 3 weeks) x 4 doses. At the end of the 4 injections carried out 21 days apart and in the absence of limiting side effects or progression justifying the cessation of the treatment according to the investigating doctor, maintenance treatment with nivolumab will be continued, at a rate of one injection every 2 weeks at a dose of 240 mg or every 4 weeks at a dose of 480 mg depending on the choice of the investigating doctor. Nivolumab will be administered for a maximum of 2 years. Patients are required to receive all four doses of NIVO+IPI before beginning NIVO monotherapy except for ipilimumab-induced toxicity compatible with nivolumab maintenance.
Kezelés: Nivolumab és Ipilimumab
- Arm B: VEGFR-TKI- ICI arm (axitinib + pembrolizumab)Egyéb csoport
Investigator's choice between: * Axitinib (5 mg oral twice a day) + pembrolizumab (200 mg flat IV every 3 weeks or 400 mg flat IV every 6 weeks). * Cabozantinib (40 mg oral, once a day away from meals) + nivolumab infusion (480 mg flat dose every 4 weeks) * Lenvatinib (20 mg oral, once a day) + pembrolizumab (200 mg flat IV every 3 weeks or 400 mg flat IV every 6 weeks)
Kezelés: Nivolumab, Pembrolizumab, Cabozantinib, Axitinib és Lenvatinib
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- First Line Randomised Study Platform to Optimize Treatment in Patients With Metastatic Renal Cell Carcinoma
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- A regiszteradat frissítve
- 2025. január 16.